Calithera Biosciences Garners $35,000,000 Series D Funding Round

  • Feed Type
  • Date
    10/25/2013
  • Company Name
    Calithera Biosciences
  • Mailing Address
    343 Oyster Point Blvd. South San Francisco, CA 94080
  • Company Description
    The primary mission of Calithera Biosciences is to develop novel therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymes. Our first program is focused on developing activators of caspases, the proteases that induce apoptosis, for the treatment of cancer.
  • Website
    http://www.calithera.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $35,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Calithera will use the proceeds from the financing to accelerate the development of the company’s lead clinical-stage candidate CB-839 through Phase 1 clinical trials in patients with advanced solid and hematological tumors.
  • M&A Terms
  • Venture Investor
    Adage Capital Management
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    Advanced Technology Ventures
  • Venture Investor
    Delphi Ventures
  • Venture Investor
    Longwood Fund